Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics

Inflammatory Bowel Diseases

Volumn 18, Issue 9, 2012, Pages 1641-1646

  Williet, Nicolas ^a   Pillot, Claire ^a   Oussalah, Abderrahim ^a   Billioud, Vincent ^a   Chevaux, Jean Baptiste ^a   Bresler, Laurent ^a   Bigard, Marc André ^a   Gueant, Jean Louis ^a   Peyrin Biroulet, Laurent ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

5 ASA; azathioprine; colectomy; infliximab; ulcerative colitis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MESALAZINE; METHOTREXATE;

ADULT; COLON RESECTION; ELECTRONIC MEDICAL RECORD; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADULT; COLECTOMY; COLITIS, ULCERATIVE; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MESALAMINE; PROGNOSIS; PROSPECTIVE STUDIES; REFERRAL AND CONSULTATION; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84865030995     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21932     Document Type: Review

References (24)

1. Filippi J, Allen PB, Hebuterne X, et al. Does Anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review. Curr Drug Targets. 2011; 12: 1440-1447.
2. Gustavsson A, Halfvarson J, Magnuson A, et al. Long-term colectomy rate after intensive intravenous corticosteroid therapy for ulcerative colitis prior to the immunosuppressive treatment era. Am J Gastroenterol. 2007; 102: 2513-2519.
3. Cohen RD, Stein R, Hanauer SB,. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol. 1999; 94: 1587-1592.
4. Rayner CK, McCormack G, Emmanuel AV, et al. Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2003; 18: 303-308.
5. Campbell S, Travis S, Jewell D,. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol. 2005; 17: 79-84.
6. Bojic D, Radojicic Z, Nedeljkovic-Protic M, et al. Long-term outcome after admission for acute severe ulcerative colitis in Oxford: the 1992-1993 cohort. Inflamm Bowel Dis. 2009; 15: 823-828.
7. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis. 2004; 10: 73-78.
8. Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006; 4: 760-765.
9. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009; 137: 1250-1260; quiz 1520.
10. Oussalah A, Evesque L, Laharie D, et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol. 2010; 105: 2617-2625.
11. Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007; 5: 103-110.
12. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994; 330: 1841-1845.
13. Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003; 125: 1025-1031.
14. Bello C, Belaiche J, Louis E, et al. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids. J Crohns Colitis. 2011; 5: 196-202.
15. Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011; 9: 483-489 e3.
16. Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut. 2011; 60: 930-936.
17. Lennard-Jones JE,. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989; 170: 2-6; discussion 16-19.
18. Joffe MM, Rosenbaum PR,. Invited commentary: propensity scores. Am J Epidemiol. 1999; 150: 327-333.
19. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55: 749-753.
20. Travis SP, Stange EF, Lemann M, et al. European evidence-based Consensus on the management of ulcerative colitis: current management. J Crohns Colitis. 2008; 2: 24-62.
21. Teisner AS, Ainsworth MA, Brynskov J,. Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: a Danish single center experience. Scand J Gastroenterol. 2010; 45: 1457-1463.
22. Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis. 2008; 2: 219-225.
23. Moore L, Gaffney K, Lopez R, et al. Comparison of the natural history of ulcerative colitis in African Americans and non-Hispanic Caucasians: a historical cohort study. Inflamm Bowel Dis. 2011; 17: 21796.
24. Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007; 132: 507-515.